Abuse liability and reinforcing efficacy of oral tramadol in humans

Drug and Alcohol Dependence

Volumn 129, Issue 1-2, 2013, Pages 116-124

  Babalonis, Shanna ^a   Lofwall, Michelle R ^a   Nuzzo, Paul A ^a   Siegel, Anthony J ^a   Walsh, Sharon L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Codeine; Human; O Desmethyltramadol (M1); Oxycodone; Self administration; Tramadol

Indexed keywords

CODEINE; OXYCODONE; TRAMADOL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SURVEILLANCE PROGRAM; DRUG USE; EYE EXAMINATION; FEMALE; HUMAN; MALE; MEDICAL LIABILITY; OUTCOME ASSESSMENT; PARTICIPANT OBSERVATION; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALGESICS, OPIOID; CARBON DIOXIDE; CODEINE; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLICKER FUSION; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; OXYCODONE; OXYGEN; PSYCHOMOTOR PERFORMANCE; PUPIL; RECEPTORS, OPIOID, MU; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TRAMADOL; YOUNG ADULT;

EID: 84875267182     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.09.018     Document Type: Article

References (61)

1. Ardakani Y.H., Rouini M.R. Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers. Biopharm. Drug Dispos. 2007, 28:527-534.
2. Barsotti C.E., Mycyk M.B., Reyes J. Withdrawal syndrome from tramadol hydrochloride. Am. J. Emerg. Med. 2003, 21:87-88.
3. Brinker A., Bonnel R.A., Beitz J. Abuse, dependence, or withdrawal associated with tramadol. Am. J. Psychiatr. 2002, 159:881. author reply 881-882.
4. Cami J., Lamas X., Farre M. Acute effects of tramadol in methadone-maintained volunteers. Drugs 1994, 47(Suppl. 1):39-43.
5. Campanero M.A., Calahorra B., Valle M., Troconiz I.F., Honorato J. Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. Chirality 1999, 11:272-279.
6. Carroll C.P., Walsh S.L., Bigelow G.E., Strain E.C., Preston K.L. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp. Clin. Psychopharmacol. 2006, 14:109-120.
7. Cicero T.J., Adams E.H., Geller A., Inciardi J.A., Munoz A., Schnoll S.H., Senay E.C., Woody G.E. A postmarketing surveillance program to monitor ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999, 57:7-22.
8. Cicero T.J., Inciardi J.A., Adams E.H., Geller A., Senay E.C., Woody G.E., Munoz A. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol. Drug Safety 2005, 14:851-859.
9. Comer S.D., Sullivan M.A., Vosburg S.K., Kowalczyk W.J., Houser J. Abuse liability of oxycodone as a function of pain and drug use history. Drug Alcohol Depend. 2010, 109:130-138.
10. Crews K.R., Gaedigk A., Dunnenberger H.M., Klein T.E., Shen D.D., Callaghan J.T., Kharasch E.D., Skaar T.C. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 2012, 91:321-326.
11. Dart R.C., Dasgupta N., Bailey J.E., Spiller H.A. Interpreting poison center call volume associated with tramadol. Ann. Pharmacother. 2011, 45:424.
12. Desmeules J.A., Piguet V., Collart L., Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br. J. Clin. Pharmacol. 1996, 41:7-12.
13. Duke A.N., Bigelow G.E., Lanier R.K., Strain E.C. Discriminative stimulus effects of tramadol in humans. J. Pharmacol. Exp. Ther. 2011, 338:255-262.
14. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Brosen K., Ossig J., Sindrup S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 2006, 102:146-150.
15. Epstein D.H., Preston K.L., Jasinski D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol. Psychol. 2006, 73:90-99.
16. Fraser H.F., Van Horn G.D., Martin W.R., Wolbach A.B., Isbell H. Methods for evaluating addiction liability, (A) " attitude" of opiate addicts toward opiate-like drugs. (B) a short-term " direct" addiction test. J. Pharmacol. Exp. Ther. 1961, 133:371-387.
17. Freye E., Levy J. Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (ultram): a case study. Eur. J. Pain 2000, 4:307-311.
18. Gillen C., Haurand M., Kobelt D.J., Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:116-121.
19. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 2004, 43:879-923.
20. IMS Health, 2012. National Prescription Audit, Top 25 Pharmaceutical Products by Dispensed Prescriptions in the US Market,. http://www.imshealth.com/.
21. Inciardi J.A., Cicero T.J., Munoz A., Adams E.H., Geller A., Senay E.C., Woody G.E. The diversion of ultram, ultracet, and generic tramadol HCL. J. Addict. Dis. 2006, 25:53-58.
22. Jasinski D.R., Griffith J.D., Pevnick J.S., Gorodetzky C., Cone E., Kay D. Progress Report from the Clinical Pharmacology Section of the NIDA Addiction Research Center, 39th Annual Meeting, The Committee on the Problems of Drug Dependence 1977, National Research Council, National Academy of Sciences, Washington, D.C., pp. 133-168.
23. Jasinski D.R., Preston K.L., Sullivan J.T., Testa M.P. Abuse potential of oral tramadol. NIDA Res. Monogr. 1993, 132:103.
24. Kim I., Barnes A.J., Oyler J.M., Schepers R., Joseph R.E., Cone E.J., Lafko D., Moolchan E.T., Huestis M.A. Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin. Chem. 2002, 48:1486-1496.
25. Kirchheiner J., Schmidt H., Tzvetkov M., Keulen J.T., Lotsch J., Roots I., Brockmoller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007, 7:257-265.
26. Lanier R.K., Lofwall M.R., Mintzer M.Z., Bigelow G.E., Strain E.C. Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berlin) 2010, 211:457-466.
27. Lofwall M.R., Walsh S.L., Bigelow G.E., Strain E.C. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berlin) 2007, 194:381-393.
28. Marquardt K.A., Alsop J.A., Albertson T.E. Tramadol exposures reported to statewide poison control system. Ann. Pharmacother. 2005, 39:1039-1044.
29. Martin W.R., Sloan B.S., Sapira J.D., Jasinski D.R. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin. Pharmacol. Ther. 1971, 12:245-258.
30. Matouskova O., Slanar O., Chytil L., Perlik F. Pupillometry in healthy volunteers as a biomarker of tramadol efficacy. J. Clin. Pharm. Ther. 2011, 36:513-517.
31. McAvoy B.R., Dobbin M.D., Tobin C.L. Over-the-counter codeine analgesic misuse and harm: characteristics of cases in Australia and New Zealand. N. Z. Med. J. 2011, 124:29-33.
32. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J.E. An automated version of the digit symbol substitution test (DSST). Behav. Res. Methods Instrum. 1982, 14:463-466.
33. Middleton L.S., Lofwall M.R., Nuzzo P.A., Siegel A.J., Walsh S.L. Intranasal oxycodone self-administration in non-dependent opioid abusers. Exp. Clin. Psychopharmacol. 2012, 20:310-317.
34. Mildh L.H., Leino K.A., Kirvela O.A. Effects of tramadol and meperidine on respiration, plasma catecholamine concentrations, and hemodynamics. J. Clin. Anesth. 1999, 11:310-316.
35. O'Connor E.C., Mead A.N. Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans. Pharmacol. Biochem. Behav. 2010, 96:279-286.
36. Oyler J.M., Cone E.J., Joseph R.E., Huestis M.A. Identification of hydrocodone in human urine following controlled codeine administration. J. Anal. Toxicol. 2000, 24:530-535.
37. Peters R.J., Williams M., Ross M.W., Atkinson J., Yacoubian G.S. Codeine cough syrup use among African-American crack cocaine users. J. Psychoactive Drugs 2007, 39:97-102.
38. Poulsen L., Arendt-Nielsen L., Brosen K., Sindrup S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 1996, 60:636-644.
39. Preston K.L., Jasinski D.R., Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend. 1991, 27:7-17.
40. Radbruch L., Grond S., Lehmann K.A. A risk-benefit assessment of tramadol in the management of pain. Drug Safety 1996, 15:8-29.
41. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J. Pharmacol. Exp. Ther. 1992, 260:275-285.
42. Romach M.K., Otton S.V., Somer G., Tyndale R.F., Sellers E.M. Cytochrome P450 2D6 and treatment of codeine dependence. J. Clin. Psychopharmacol. 2000, 20:43-45.
43. SAMHSA Results from the 2006 National Survey on Drug Use and Health: National Findings 2007, Substance Abuse and Mental Health Administration, Rockville, MD.
44. Schuster C.R., Smith B.B., Jaffe J.H. Drug abuse in heroin users. An experimental study of self-administration of methadone, codeine, and pentazocine. Arch. Gen. Psychiatr. 1971, 24:359-362.
45. Senay E.C., Adams E.H., Geller A., Inciardi J.A., Munoz A., Schnoll S.H., Woody G.E., Cicero T.J. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend. 2003, 69:233-241.
46. Skipper G.E., Fletcher C., Rocha-Judd R., Brase D. Tramadol abuse and dependence among physicians. J. Am. Med. Assoc. 2004, 292:1818-1819.
47. Spiller H.A., Scaglione J.M., Aleguas A., Foster H., Durback-Morris L., Scharman E.J., Baker S.D. Effect of scheduling tramadol as a controlled substance on poison center exposures to tramadol. Ann. Pharmacother. 2010, 44:1016-1021.
48. Stacher G., Steinringer H., Schneider S., Mittelbach G., Gaupmann G., Abatzi T.A., Stacher-Janotta G. Effects of graded oral doses of a new 5-hydroxytryptamine/noradrenaline uptake inhibitor (Ro 15-8081) in comparison with 60mg codeine and placebo on experimentally induced pain and side effect profile in healthy men. Br. J. Clin. Pharmacol. 1987, 24:627-635.
49. Stoops W.W., Hatton K.W., Lofwall M.R., Nuzzo P.A., Walsh S.L. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berlin) 2010, 212:193-203.
50. Stoops W.W., Lofwall M.R., Nuzzo P.A., Craig L.B., Siegel A.J., Walsh S.L. Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berlin) 2012, 223:427-438.
51. Sudheer P.S., Logan S.W., Terblanche C., Ateleanu B., Hall J.E. Comparison of the analgesic efficacy and respiratory effects of morphine, tramadol and codeine after craniotomy. Anaesthesia 2007, 62:555-560.
52. Tarkkila P., Tuominen M., Lindgren L. Comparison of respiratory effects of tramadol and oxycodone. J. Clin. Anesth. 1997, 9:582-585.
53. Tjaderborn M., Jonsson A.K., Hagg S., Ahlner J. Fatal unintentional intoxications with tramadol during 1995-2005. Forensic Sci. Int. 2007, 173:107-111.
54. Volpe D.A., McMahon Tobin G.A., Mellon R.D., Katki A.G., Parker R.J., Colatsky T., Kropp T.J., Verbois S.L. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul. Toxicol. Pharmacol. 2011, 59:385-390.
55. Walker D.J., Zacny J.P. Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology (Berlin) 1998, 140:191-201.
56. Walsh S.L., Nuzzo P.A., Lofwall M.R., Holtman J.R. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008, 98:191-202.
57. Warren P.M., Taylor J.H., Nicholson K.E., Wraith P.K., Drummond G.B. Influence of tramadol on the ventilatory response to hypoxia in humans. Br. J. Anaesth. 2000, 85:211-216.
58. Watson W.A., Litovitz T.L., Rodgers G.C., Klein-Schwartz W., Youniss J., Rose S.R., Borys D., May M.E. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 2003, 21:353-421.
59. Wu W.N., McKown L.A., Liao S. Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 2002, 32:411-425.
60. Yanagita T. Drug dependence potential of 1-(m-methoxyphenyl)-2-dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in monkeys. Arzneimittelforschung 1978, 28:158-163.
61. Zacny J.P. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. Drug Alcohol Depend. 2005, 80:273-278.